Subscribe to RSS
DOI: 10.1055/s-2007-991652
© Georg Thieme Verlag KG Stuttgart · New York
Beta-Rezeptorenblocker und ACE-Hemmer
Vergleich von Carvedilol und Metoprolol als Kombinationspartner bei Diabetes und arterieller HypertonieBeta-adrenoceptor antagonists and ACE-inhibitorsCarvedilol compared with metoprolol as combination partner in cases of diabetes and hypertensionPublication History
eingereicht: 17.7.2007
akzeptiert: 4.10.2007
Publication Date:
24 October 2007 (online)

Zusammenfassung
Nahezu alle Typ-2-Diabetiker leiden an einer arteriellen Hypertonie, die in der Regel noch vor dem Diabetes manifest wird. Die konsequente Einstellung der arteriellen Hypertonie erfordert häufig eine Zweifachkombination aus Angiotensin Converting Enzyme(ACE)-Hemmer und β-Rezeptorenblocker. Metoprolol ist der häufigste verwendete β-Blocker. Klinische Studien weisen auf eine Überlegenheit von Carvedilol bezüglich der Qualität der Stoffwechseleinstellung und der Vermeidung von Folgestörungen des Diabetes hin. Daher scheint Carvedilol der β-Rezeptorenblocker der Wahl für Patienten mit hohem kardiovaskulären Risiko und insbesondere Typ-2-Diabetiker zu sein. Wegen fehlender Vergleiche zu Metoprolol-Succinat sowie zu optimal dosiertem Metoprolol-Tartrat kann aber nicht von einer sicheren Überlegenheit von Carvedilol ausgegangen werden.
Summary
Nearly all type 2 diabetic patients are suffering from arterial hypertension. The latter usually becomes manifest earlier than the diabetic metabolic disturbances. Adequate treatment often requires a combination of angiotensin converting enzyme(ACE)-inhibitors and β-adrenoceptor antagonists. Metoprolol is still the most frequently used β-adrenoceptor antagonist in this setting. Some clinical trials have shown carvedilol to be superior in improving the metabolic situation and prevention of secondary disorders caused by diabetes. Therefore carvedilol may be the β-adrenoceptor antagonist of choice for treatment of patients at high cardiovascular risk and especially for diabetes type 2. As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed.
Schlüsselwörter
Diabetes - arterielle Hypertonie - β-Blocker - Metoprolol - Carvedilol
Key words
diabetes - arterial hypertension - β-adrenoceptor antagonists - metoprolol - carvedilol
Literatur
- 1
Baghestanian M.
Stellenwert der Betablocker in der antihypertensiven Therapie von PAVK-Patienten.
Zeitschrift für Gefäßmedizin.
2006;
3
11-16
MissingFormLabel
- 2
Bakris G L, Fonseca V, Katholi R E. et al .
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
Hypertension.
2005;
46
1309-1315
MissingFormLabel
- 3
Bakris G L, Fonseca V, Katholi R E. et al .
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus
and hypertension: a randomized controlled trial.
JAMA.
2004;
292
2227-2236
MissingFormLabel
- 4
Bell D S.
Advantages of a third-generation beta-blocker in patients with diabetes mellitus.
Am J Cardiol.
2004;
93
49B-52B
MissingFormLabel
- 5
Cheng J, Kamiya K, Kodama I.
Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Cardiovasc Drug Rev.
2001;
19
152-171
MissingFormLabel
- 6
Giugliano D, Acampora R, Marfella R. et al .
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent
diabetes mellitus and hypertension. A randomized, controlled trial.
Ann Intern Med.
1997;
126
955-959
MissingFormLabel
- 7
Kindermann M, Maack C, Schaller S. et al .
Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete
elimination from plasma in vivo.
Circulation.
2004;
109
3182-3190
MissingFormLabel
- 8
Kurtz T W, Pravenec M.
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin
II receptor antagonists: beyond the renin-angiotensin system.
J Hypertens.
2004;
22
2253-2261
MissingFormLabel
- 9
Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C.
Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.
Am J Cardiovasc Drugs.
2006;
6
209-217
MissingFormLabel
- 10
McBride, White C M.
Critical differences among beta-adrenoreceptor antagonists in myocardial failure:
debating the MERIT of COMET.
J Clin Pharmacol.
2005;
45
6-24
MissingFormLabel
- 11
McTavish D, Campoli-Richards D, Sorkin E M.
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic
efficacy.
Drugs.
1993;
45
232-258
MissingFormLabel
- 12
Morgan T.
Clinical pharmacokinetics and pharmacodynamics of carvedilol.
Clin Pharmacokinet.
1994;
26
335-346
MissingFormLabel
- 13
Poole-Wilson P A, Swedberg K, Cleland J G. et al .
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic
heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled
trial.
Lancet.
2003;
362
7-13
MissingFormLabel
- 14
Segura J, Ruilope L M.
Antihypertensive therapy in patients with metabolic syndrome.
Curr Opin Nephrol Hypertens.
2006;
15
493-497
MissingFormLabel
- 15
Stahl E, Henke D, Mutschler E, Spahn-Langguth H.
Saturable enantioselective first-pass effect for carvedilol after high oral racemate
doses in rats.
Arch Pharm (Weinheim).
1993;
326
123-125
MissingFormLabel
- 16
Stoschitzky K, Koshucharova G, Lercher P. et al .
Stereoselective effects of (R)- and (S)-carvedilol in humans.
Chirality.
2001;
13
342-346
MissingFormLabel
- 17
Stoschitzky K, Koshucharova G, Zweiker R. et al .
Differing beta-blocking effects of carvedilol and metoprolol.
Eur J Heart Fail.
2001;
3
343-349
MissingFormLabel
Prof. Dr. med. habil. Hagen Sandholzer
Selbstständige Abteilung für Allgemeinmedizin der Universität Leipzig
Philip Rosenthal-Straße 51
04103 Leipzig
Phone: +49 341 9715710
Fax: +49 341 9715719
Email: sanh@medizin.uni-leipzig.de